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Pathogenic strains of the genus Acanthamoeba are causative agents of severe infections, such as fatal
encephalitis and a sight-threatening amoebic keratitis. Antimicrobial therapy for these infections is generally
empirical, and patient recovery is often problematic, due to the existence of a highly resistant cyst stage in these
amoebae. In previous studies, small interfering RNAs (siRNAs) against the catalytic domains of extracellular
serine proteases and glycogen phosphorylase from Acanthamoeba were designed and evaluated for future
therapeutic use. The silencing of proteases resulted in Acanthamoeba failing to degrade human corneal cells,
and silencing of glycogen phosphorylase caused amoebae to be unable to form mature cysts. After the siRNA
design and concentration were optimized in order to avoid toxicity problems, cultures of Acanthamoeba were
treated with a combination of both siRNAs, and cells were evaluated under an inverted microscope. This
siRNA-based treatment dramatically affected the growth rate and cellular survival of the amoebae. These
results were observed less than 48 h after the initiation of the treatment. In order to check possible toxic effects
of the siRNA combination, three eukaryotic cell lines (HeLa, murine macrophages, and osteosarcoma cells)
were treated with the same molecules, and cytotoxicity was examined by measuring lactate dehydrogenase
release. The future use of the combination of these siRNAs is proposed as a potential therapeutic approach
against pathogenic strains of Acanthamoeba.
Acanthamoeba species are opportunistic agents of dissemi-
nated infections (mostly cutaneous and nasopharyngeal infec-
tions), a sight-threatening ulceration of the cornea called
Acanthamoeba keratitis (AK), and a fatal form of encephalitis
known as Acanthamoeba granulomatous encephalitis (AGE)
(2, 7, 11, 16).
Current therapeutic measures for Acanthamoeba keratitis
rely on topical applications of antimicrobials, including a com-
bination of propamidine isethionate and neomycin or chlo-
rhexidine. However, the length of these treatments makes the
process arduous. Furthermore, as the treatments are poorly
effective against the cyst stage of the protozoan, residual in-
fection often remains in these cases (3, 7, 17). No fully effective
treatment against AGE has been established, although thera-
peutic measures have been used with apparent effect as an
adjunct to surgery (6, 7, 8, 12, 17, 19).
Pathogenic and nonpathogenic Acanthamoeba strains have
been isolated from the environment, but the amoebic deter-
minants vital to pathogenesis are poorly understood. Patho-
genic Acanthamoeba strains have greater temperature toler-
ance, growth rates, and adherence properties; more secreted
cytotoxic products; and better immune evasion mechanisms
than nonpathogenic Acanthamoeba strains (6, 7, 11).
The pathogenesis of Acanthamoeba infection is dependent
upon host and amoebic factors, as well as environmental as-
pects, such as temperature and osmotic pressure. Amoebic
factors seemed to be mediated by adhesion to the host cell,
followed by the secretion of proteases (mainly serine pro-
teases), phagocytosis, and direct killing of the host cell (7).
Small interfering RNA (siRNA) is the most essential and
best-known double-stranded RNA (dsRNA) that is used for
RNA interference (RNAi). It follows the exogenous pathway
of gene silencing, as it is usually not present in the cell and is
incorporated artificially, or it may infect the cell through cer-
tain viruses that have RNA as their genetic material (15). Since
it can be synthesized artificially, it may be considered for use as
a potent therapeutic agent. siRNA is produced from long
dsRNA precursors that are further formed by folding of single-
stranded RNA (ssRNA) molecules. In certain cases, it is also
produced by using primary siRNA as a template and recruiting
RNA-dependent RNA polymerase for the synthesis reaction.
siRNA is usually long and cannot interact directly with the
RNAi machinery to cause gene silencing. As a result, process-
ing of siRNA takes place, which generates 21- to 23-bp-long
siRNA that is responsible for causing gene silencing of a ho-
mologous target mRNA. Depending on the nature of the loci
and biogenesis of the dsRNA precursor, different versions of
siRNAs have been identified (18).
RNAi appears promising for silencing gene expression in
parasitic pathogens, such as protozoans and helminths, as well
as disease vectors, by specific target mRNA interference (9, 10,
18, 20). Analysis of gene functions in pathogens of infectious
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diseases and their vectors is important for research in drug
development, and the silencing effects may be directly em-
ployed to control parasite transmission and development.
Since it was first applied in the genus Acanthamoeba (9), a
few genes involved in Acanthamoeba pathogenesis and the
formation of mature cysts have been silenced using siRNA in
order to identify them as possible targets for chemotherapy
and gene therapy or as key items in cellular functions (4, 9, 10,
13, 14). In previous studies, extracellular serine proteases were
silenced using siRNAs, resulting in the Acanthamoeba organ-
isms not being able to degrade human corneal cells (9). More
recently, it was established by using siRNAs that serine pro-
teases also play an important role in trophozoite differentiation
and reemergence during excystment (4). Furthermore, the role
of glycogen phosphorylase in the formation of mature cysts in
Acanthamoeba was also established recently by using siRNA
(10). Thus, blocking the entry and exit paths of these amoebae
during their pathogenesis process could be achieved by using
these siRNA molecules.
The results of the present study suggest that the combination
of these two gene-specific siRNAs may be useful as a future
therapeutic approach for the treatment of infectious processes
caused by Acanthamoeba.
MATERIALS AND METHODS
Culture of Acanthamoeba. Acanthamoeba castellanii Neff (ATCC 30010, geno-
type T4), a type strain from the American Type Culture Collection, was used in
this study. Three clinical strains (CLC-16, genotype T3; CLC-41.r, genotype T4;
and CLC-51.l, genotype T1) previously isolated from contact lens cases were also
included in the study (12). These strains were axenically grown in PYG medium
(0.75% [wt/vol] proteose peptone, 0.75% [wt/vol] yeast extract, and 1.5% [wt/vol]
glucose) containing 40 g gentamicin ml1 (Biochrom AG, Cultek, Granollers,
Barcelona, Spain) prior to their use in the assays. Amoebae grown in this way
were then seeded in 24-well plates at a concentration of 104 cells per well.
Gene-silencing procedure and encystation conditions. The soaking method,
previously and successfully applied to Acanthamoeba gene silencing (9, 10), was
used in the study. Regarding the siRNAs, two different molecules that were
designed and validated in previous studies (9, 10) were used in this work. These
molecules target the catalytic domains of extracellular serine proteases (SP-
siRNA) and the glycogen phosphorylase gene in Acanthamoeba (GP-siRNA).
The application of these siRNAs at a maximum concentration of 15 g ml1
each (in order to avoid toxicity problems) was carried out in Costar 24-well cell
culture clusters (Corning, Madrid, Spain). These experiments were carried out 3
times in duplicate.
Briefly, trophozoites (104 ml1) of each amoebic strain were seeded in the
plates containing PYG medium until they formed an almost confluent mono-
layer. At this stage, 15 g ml1 of SP-siRNA was introduced into the cells using
the X-tremeGene siRNA transfection reagent (Roche Diagnostics, Barcelona,
Spain). After 24 h of incubation with SP-siRNA, the PYG medium was poured
off and immediately replaced with Neff’s encystment medium (NEM) in order to
simulate a tear-like effect that in the human eye causes the trophozoites physical
and osmotic stress (Fig. 1A). Thus, induction of amoebic encystation was trig-
gered, as this procedure is the main exit path of Acanthamoeba against any
stressful environmental conditions, resulting in the formation of a highly resistant
double-wall mature cyst. Simultaneously, after NEM was added, 15 l ml1 of
GP-siRNA was added to the cells, using the same siRNA transfection reagent.
Controls with only amoebae in PYG medium and NEM alone, and also with
one of the siRNAs (SP-siRNA or GP-siRNA only in PYG and NEM) at the same
concentrations used in the experiment, were simultaneously developed. A con-
trol with scrambled siRNA from a sequence absent from the genus Acan-
thamoeba and based on the gene encoding the green fluorescent protein was used
as previously described (9, 10).
Microscopy. During the silencing procedure, cells were monitored using a
DMIL inverted microscope (Leica, Wetzlar, Germany) at different time intervals
in order to check for phenotypic manifestations in the siRNA-treated cells
compared to the control cells.
Cell lines. The following cell lines were used in this study: J774A.1 murine
macrophages (ATCC TIB-67), HeLa cells (ATCC CCL-2), and the U-2 OS
osteosarcoma cell line (ATCC HTB-96) were purchased from the American
Type Culture Collection (ATTC) (LG Promochem, Barcelona, Spain). The three
cell lines were maintained as monolayer cultures at 37°C in 5% CO2 in T-75
culture flasks (Corning, Madrid, Spain). Cells were routinely cultured in Dul-
becco’s modified Eagle medium without phenol red (DMEM) (Sigma, Tres
Cantos, Madrid, Spain) supplemented with 10% fetal calf serum, 2 mM glu-
tamine, and 20 g ml1 gentamicin (Biochrom AG, Cultek, Granollers, Barce-
lona, Spain) and subcultured two times per week.
Cytotoxicity assays. Cytotoxicity assays were performed using a cytotoxicity
detection kit based on the release of lactate dehydrogenase enzyme (LDH)
(Roche Diagnostics, Sant Cugat del Valle`s, Barcelona, Spain) as previously
described (1, 9). Briefly, the three cell lines were grown to monolayers in 6-well
plates. Next, the cells were incubated with SP-siRNA, GP-siRNA, or both siR-
NAs at the same concentrations and under the same conditions that were used
for the treatment of the Acanthamoeba strains. The cell lines were then incu-
bated in fetal calf serum-free DMEM at 37°C in 5% CO2. The cell monolayers
were observed periodically for cytopathic effects for up to 48 h. At the end of this
incubation period, cytopathic effects were assessed visually after hematoxylin
staining. In addition, the supernatants were collected and cytotoxicity was de-
termined by measuring LDH release following the manufacturer’s instructions.
Control values were obtained from each cell line incubated alone in fetal calf
serum-free DMEM without phenol red. Total LDH release was determined from
each cell line treated with 2% Triton X-100 (Sigma, Tres Cantos, Madrid, Spain).
These experiments were carried out 3 times in duplicate. Cytotoxicity values
between 0% and 10% were considered not cytotoxic, and cytotoxicity values
between 10 and 25% were considered low, whereas cytotoxicity values from 25%
to 40% were considered moderate levels. Values higher than 40% and up to
100% were considered high cytotoxicity levels.
Sensitivity and viability assays. Acanthamoeba cell viability was determined by
trypan blue staining (trypan blue solution, 0.4%, liquid, sterile filtered, and cell
culture tested; Sigma, Tres Cantos, Madrid, Spain). Quantification of cell via-
bility was performed at 0, 24, 48, 72, and 96 h using a hemocytometer.
To test the resistance of Acanthamoeba precysts and cysts, a 5-min treatment
with a nonionic detergent (SDS; 0.5% [wt/vol] final concentration) was used as
previously described (10).
RESULTS
The addition of SP-siRNA caused the cytoplasm of amoebae
to become full of vesicles, and their growth rate was lower than
that of the control cells. After 24 h of incubation with the
SP-siRNA, it was observed that the SP-siRNA-treated amoe-
bae lowered their division rate in comparison to the control
cells (Fig. 1A). At this stage, the PYG medium was removed
and replaced by NEM (see Materials and Methods) (Fig. 1A),
and GP-siRNA was added to the previously SP-siRNA-treated
amoebae. The cells were then monitored for the next 24 h.
These double-siRNA-treated cells (SP-siRNA at 0 h plus GP-
siRNA after 24 h) were unable to start the formation of a
mature cyst stage, and no immature cysts were detected in the
wells until 24 h after the induction of osmotic stress (replace-
ment of PYG medium by NEM). Interestingly, GP-siRNA-
treated amoebae in NEM seemed unable to start the encysta-
tion process and also detached from the culture flask. Similar
cell behavior was observed in the control well treated only with
SP-siRNA and kept in NEM. A very low growth rate in the
control amoebae in PYG medium treated with SP-siRNA was
also observed at this stage (Fig. 1B).
At 48 h after the addition of SP-siRNA, amoebae treated
with the combination of SP-siRNA and GP-siRNA were all
detached from the bottom of the flask. Moreover, most of the
cells were dead (they failed to exclude trypan blue), and the
remaining amoebae (trophozoites and/or rounded cells) did
not survive a 5-min treatment with 0.5% SDS and underwent
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cell lysis. Thus, the combination of both siRNAs eliminated the
amoebae in 48 h, causing cell lysis in most of the amoebae. The
rest of the amoebae left in the well were dead, as they also
failed to exclude trypan blue (Fig. 1B).
The number of cells of the control amoebae in PYG
medium was much higher than that of the amoebae treated
with SP-siRNA, also in PYG medium, at this stage. More-
over, amoebae incubated with SP-siRNA or GP-siRNA
alone were not able to form mature cysts in NEM, and only
trophozoites or rounded cells were observed in these wells.
These rounded cells were viable but did not resist a 5-min
treatment with 0.5% SDS.
The control with scrambled siRNA and the control with only
amoebae (PYG changed to NEM) grew at a normal rate and
underwent a normal encystment process when NEM was
added (Fig. 2A and B). It was possible to observe mature cysts
(with both cyst layers) at 24 to 48 h postinduction of encysta-
tion in these wells. Controls consisting of amoebae alone and
amoebae treated with siRNA-GP alone in PYG medium
showed a confluent monolayer of trophozoites (Fig. 1B).
For the cytotoxicity assays, the same pattern of siRNA
treatment was used. First, SP-siRNA was added to the cell
cultures, and after 24 h, GP-siRNA was also introduced into
the cell cultures. At 24 h, all three tested cell lines showed
cytotoxicity levels between 10 and 30% when treated with
either SP-siRNA or GP-siRNA (Table 1). At 48 h, cells
treated with the combination of both siRNAs exhibited cy-
totoxicity levels around 37% (36.91%  3.56) (Table 1),
whereas the cytotoxicity levels in the cells incubated with
SP- or GP-siRNA alone for 48 h were between 18 and 38%
and 24 and 38%, respectively (Table 1).
DISCUSSION
A powerful and effective application of siRNAs as a thera-
peutic tool against the genus Acanthamoeba is presented in this
FIG. 1. The tear model proposed in this study and the treatment scheme undertaken with both siRNAs. Briefly, amoebae were grown in PYG
medium and incubated with SP-siRNA (A). After 24 h, the PYG medium was poured off and replaced by NEM (encystation medium). The
amoebae under these conditions were then incubated with GP-siRNA (B). The light microscopy (20 and 40) images correspond to the assays
that were carried out with A. castellanii Neff ATCC 30010; similar results were obtained with the other clinical strains included in this study.
Controls are shown, as well as the cell numbers (trophozoites, precysts, and cysts) in each well. 2siRNAs indicates that the amoebae were incubated
with both siRNAs. PYG3NEM is a control without the addition of siRNAs but with a change of medium (induction of encystation). Differences
between replicate experiments were insignificant.
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study. Combinations of two different siRNAs (SP-siRNA and
GP-siRNA) specific to Acanthamoeba genes and previously
developed by our group were used in this work. Extracellular
serine proteases are directly involved in the pathogenicity of
Acanthamoeba; moreover, larger quantities of extracellular
serine proteases are secreted by pathogenic strains than by
nonpathogenic strains (5, 7, 9).
SP-siRNAs were added to different pathogenic strains of
Acanthamoeba in our previous work (9). In that case, Acan-
thamoeba failed to secrete large amounts of extracellular
serine proteases and mRNAs were also lower, and thus, cyto-
toxic effects on human corneal cells in vitro were negligible
compared to those of controls consisting of Acanthamoeba
cells not treated with the SP-siRNAs. Also, it was demon-
strated by real-time PCR that the silencing phenomenon was
stable up to 96 h after introduction of the SP-siRNA. More-
over, in a recent study, the same SP-siRNAs were used against
trophozoites of Acanthamoeba belonging to the T4 genotype,
demonstrating that these siRNAs were able to block the en-
cystment and excystment processes in this strain of Acan-
thamoeba (4). On the other hand, using siRNA-based meth-
ods, our group recently reported that glycogen phosphorylase
is required for cyst wall assembly, mainly for the formation of
the cell wall inner layer. This observation was proven by treat-
ing amoebae with specific GP-siRNA and simultaneously in-
ducing encystation by changing PYG medium to NEM. Acan-
thamoeba cells treated with these siRNAs were able to form
only single-layered immature cysts up to 96 h after treatment,
and they were degraded in less than 5 min when treated with
0.5% SDS. In comparison, control cells free of GP-siRNA
formed mature cysts 24 h after the induction of encystation. At
the molecular level, no glycogen phosphorylase mRNAs or
protein or activity of the enzyme was detected up to 96 h after
treatment with GP-siRNA, confirming the gene-silencing phe-
nomenon (10).
In our experiments in this work and 24 h after the addition
of SP-siRNA, it was clear that the SP-siRNA-treated amoebae
lowered their division rate in comparison to the control cells
(Fig. 1 and 2). At this stage, the PYG medium was removed
and replaced by NEM, and also, GP-siRNA was added to the
previously SP-siRNA-treated amoebae. The cells were then
monitored for the next 24 h. The double-treated cells (SP-
siRNA at 0 h plus GP-siRNA after 24 h) did not form mature
double-wall cysts, and no signs of initial stages of encystment
were observed (Fig. 1B). This observation supports our previ-
ous molecular data regarding the status of both extracellular
serine protease and glycogen phosphorylase genes at this stage.
Interestingly, Acanthamoeba cells were not able to start encys-
tation, which is in accordance with the previous report of a
major role of serine proteases in the encystment and excyst-
ment processes in Acanthamoeba (4).
Control amoebae treated with GP-siRNA only in NEM were
not able to initiate the encystation process but detached from
the culture flask, a very early sign of encystment (Fig. 1 and 2).
As mentioned above, silencing of glycogen phosphorylase re-
sulted in the formation of single-layered immature cysts but
not double-wall mature cysts (10). Similar behavior was ob-
served in the control with SP-siRNA in NEM (Fig. 1 and 2),
again supporting the previous observations by our group and
recently by Dudley et al. (4). Amoebae cultured in PYG me-
dium and treated with SP-siRNA alone showed a very low
growth rate compared to the control nontreated cells in PYG
medium. Furthermore, no changes were observed in amoebae
treated with GP-siRNA in PYG medium (Fig. 1 and 2).
At 48 h after the introduction of SP-siRNA and 24 h after
the addition of GP-siRNA, amoebae treated with this combi-
nation of siRNAs all detached from the bottom of the flask,
following our previous observations (10). However, most of the
cells were dead, and the remaining amoebae (trophozoites
and/or rounded cells or single-layered immature cysts) did not
survive a 5-min treatment with 0.5% SDS (a test for the sen-
sitivity of cysts) and underwent cell lysis (Fig. 1 and 2). There-
fore, the results obtained with the combination of both siRNAs
TABLE 1. Percentages of cytotoxicity in the three tested eukaryotic
cell lines caused by SP-siRNA and GP-siRNA alone
and in combination
Time (h) Cell line
% Cytotoxicity
SP-siRNA GP-siRNA 2siRNAa
24 Macrophages 13.23  2.05 27.9 2.2 34.14 1.38
HeLa 11.73 2.35 30.7 4.11 30.9 6.04
U20S 23.02 1.9 21.2 5.97 21.13 1.24
48 Macrophages 20.14  5.88 29.1 4.07 37.18 5.96
HeLa 18.87 3.34 38 2.87 35.69 2.24
U20S 38.83 4.98 24.8 3.73 36.91 3.56
a 2siRNA, SP-siRNA and GP-siRNA in combination.
FIG. 2. Numbers of cells at 72 h (A) and 96 h (B). 2siRNAs indi-
cates that the amoebae were incubated with both siRNAs.
PYG3NEM is a control without the addition of siRNAs but with a
change of medium (induction of encystation). Differences between
replicate experiments were insignificant.
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as a therapeutic tool demonstrated that these molecules at a
concentration of 15 g ml1 are able to eliminate clinical
strains of Acanthamoeba in 48 h.
Another interesting observation at this stage was that amoe-
bae incubated with SP-siRNA or GP-siRNA in NEM were not
able to form mature cysts, and only trophozoites or rounded
cells were observed in these wells, supporting the previous
reports mentioned above (4, 9, 10).
Amoebae treated with GP-siRNA alone in PYG medium
showed a confluent monolayer of trophozoites, and thus, gly-
cogen phosphorylase does not seem to be involved in any key
processes of Acanthamoeba at the trophozoite stage (Fig. 1 and
2). This observation supports our previous data, as no expres-
sion of glycogen phosphorylase was detectable in actively grow-
ing and stationary trophozoites (10).
In the cytotoxicity assays, SP-siRNA or GP-siRNA alone
caused very low cytotoxicity to the three cell lines after 24 h of
incubation (Table 1). The combination of both siRNAs also
caused low cytotoxicity after 24 h. However, after 48 h, siRNAs
alone or in combination caused moderate rates of cytotoxicity
(between 20 and 37%) (Table 1). Therefore, this observation
should be considered in order to further develop this thera-
peutic approach. It may be possible to develop liposomal for-
mulations that include these siRNAs or another vehicle of
administration for a future siRNA-based amoebicidal agent,
which could decrease the cytotoxicity levels caused by these
molecules, as well as to develop in vivo models to evaluate this
combination of siRNAs at this level.
Overall, the combination of SP-siRNAs and GP-siRNAs
against the strains of Acanthamoeba included in this study
appears to be a very powerful and effective approach for the
establishment and development of more effective treatments
for Acanthamoeba infections.
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